HbO2 Therapeutics

HbO2 Therapeutics, a 2014-founded biotechnology startup based in the United States, specializes in developing and manufacturing oxygen carrying solutions aimed at increasing the amount of oxygen transported throughout the body. The company's product portfolio includes Hemopure® and Oxyglobin®, intended for human and veterinary use respectively. Notably, Oxyglobin is the sole FDA and EMA-approved oxygen carrying solution for canine anemia treatment. Hemopure, on the other hand, is sanctioned for specific applications in South Africa and Russia, while in the US, it is available under investigational status via the FDA expanded access program for qualifying patients with severe, life-threatening anemia who cannot undergo blood transfusions. This scenario may arise due to religious beliefs or the unavailability of compatible blood for transfusion. With its slogan "We offer a solution when blood transfusion is not an option," HbO2 Therapeutics focuses on addressing critical medical needs in the healthcare and wellness industry, supported by its activities in the manufacturing and platforms sectors. Notably, the startup's recent investment details and involved investors are currently unavailable, but its groundbreaking innovations and potential impact in providing alternative solutions for anemic patients pose an intriguing opportunity for venture capital investors in the health-focused biotech space.